Exact Sciences Corp
NASDAQ:EXAS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
41.33
75.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Exact Sciences Corp
Wall Street
Price Targets
EXAS Price Targets Summary
Exact Sciences Corp
According to Wall Street analysts, the average 1-year price target for
EXAS
is 73.64 USD
with a low forecast of 60.6 USD and a high forecast of 93.67 USD.
EXAS Last Price Targets
Exact Sciences Corp
The latest public price target was made on Nov 6, 2024 by
Catherine Schulte
from
Robert W. Baird
,
who expects
EXAS
stock to
rise by 13%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Catherine Schulte
Robert W. Baird
|
67
USD
Upside 13% |
1 month ago
Nov 6, 2024
|
Exact Sciences (EXAS) PT Lowered to $67 at Baird
StreetInsider
|
|
Mark Massaro
BTIG
|
65
USD
Upside 9% |
1 month ago
Nov 6, 2024
|
Exact Sciences (EXAS) PT Lowered to $65 at BTIG
StreetInsider
|
Kyle Mikson
Canaccord Genuity
|
95
USD
Upside 60% |
1 month ago
Oct 29, 2024
|
Exact Sciences (EXAS) PT Raised to $95 at Canaccord Genuity
StreetInsider
|
Vijay Kumar
Evercore ISI
|
80
USD
Upside 35% |
2 months ago
Oct 1, 2024
|
Exact Sciences price target raised to $80 from $72 at Evercore ISI
TheFly
|
|
Mark Massaro
BTIG
|
82
USD
Upside 38% |
3 months ago
Sep 16, 2024
|
Exact Sciences price target raised to $82 from $70 at BTIG
TheFly
|
Patrick Donnelly
Citigroup
|
80
USD
Upside 35% |
3 months ago
Sep 16, 2024
|
Citi Reiterates Buy Rating on Exact Sciences (EXAS)
StreetInsider
|
|
Kyle Mikson
Canaccord Genuity
|
75
USD
Upside 26% |
3 months ago
Sep 13, 2024
|
Canaccord Genuity Reiterates Buy Rating on Exact Sciences (EXAS)
StreetInsider
|
David Westenberg
Piper Sandler
|
85
USD
Upside 43% |
3 months ago
Sep 12, 2024
|
Exact Sciences (EXAS) PT Raised to $85 at Piper Sandler
StreetInsider
|
|
David Westenberg
Piper Sandler
|
80
USD
Upside 35% |
5 months ago
Jul 19, 2024
|
Piper Sandler Reiterates Overweight Rating on Exact Sciences (EXAS)
StreetInsider
|
|
Mark Massaro
BTIG
|
70
USD
Upside 18% |
5 months ago
Jun 26, 2024
|
Exact Sciences price target lowered to $70 from $80 at BTIG
TheFly
|
Sung Ji Nam
Scotiabank
|
70
USD
Upside 18% |
5 months ago
Jun 26, 2024
|
Exact Sciences initiated with an Outperform at Scotiabank
TheFly
|
Tycho Peterson
Jefferies
|
75
USD
Upside 26% |
6 months ago
Jun 3, 2024
|
Exact Sciences assumed with a Buy at Jefferies
TheFly
|
|
Kyle Mikson
Canaccord Genuity
|
85
USD
Upside 43% |
7 months ago
May 9, 2024
|
Exact Sciences price target lowered to $85 from $90 at Canaccord
TheFly
|
|
Patrick Donnelly
Citigroup
|
130
USD
Upside 119% |
1 year ago
Jun 22, 2023
|
Exact Sciences Set To Dominate Emerging Precision Oncology Market: Analyst Applauds $18B Potential Market
Benzinga
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is EXAS's stock price target?
Price Target
73.64
USD
According to Wall Street analysts, the average 1-year price target for
EXAS
is 73.64 USD
with a low forecast of 60.6 USD and a high forecast of 93.67 USD.
What is Exact Sciences Corp's Revenue forecast?
Projected CAGR
11%
For the last 8 years the
compound annual growth rate for
Exact Sciences Corp's revenue is
68%.
The projected
CAGR
for the next 4 years is
11%.
You don't have any saved screeners yet
